Ann: Phase One and Two Clinical Program Update, page-14

"...may I ask why you haven't found a reason to hit the buy trigger?" – I'm overexposed to micro-cap med-tech and pharma-research stocks at the moment so I would need to have an extraordinarily high level of confidence in that kind of stock before I would buy yet more. I keep watching because I've invested a considerable amount of time and effort in the company in the past and I'd hate to look away and miss the re-entry moment.

The company has delivered some key criteria already:

1. Ditched Mente
2. Ditched everybody associated with Mente
3. Assembled a credible replacement team
4. Accumulated credible funding for operations

At the risk of boring people who've already seen these criteria, I would still want to see at least some of the following starting to happen:

1. A specific target condition (or conditions) for efficacy testing in clinical trials
2. A credible clinical trial design
3. A credible commercialisation plan, which could see the product on the market as a dietary supplement rather than a controlled pharmaceutical

Hope that answers your question.